Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
Public ClinicalTrials.gov record NCT00098332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma
Study identification
- NCT ID
- NCT00098332
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- forodesine hydrochloride Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2004
- Primary completion
- Nov 30, 2010
- Completion
- Jun 30, 2011
- Last update posted
- Jul 9, 2013
2004 – 2011
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham | Birmingham | Alabama | 35294 | — |
| Burke Pharmaceutical Research | Hot Springs | Arkansas | 71913 | — |
| Stanford Comprehensive Cancer Center - Stanford | Stanford | California | 94305 | — |
| University of Colorado Cancer Center at UC Health Sciences Center | Aurora | Colorado | 80045 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520-8028 | — |
| Cancer and Blood Disease Center | Lecanto | Florida | 34461 | — |
| Dana-Farber/Brigham and Women's Cancer Center | Boston | Massachusetts | 02115 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| Charles M. Barrett Cancer Center at University Hospital | Cincinnati | Ohio | 45219 | — |
| M.D. Anderson Cancer Center at University of Texas | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00098332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2013 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00098332 live on ClinicalTrials.gov.